OTCStockReview.com News Commentary
ATLANTA, Jan. 22, 2020 (GLOBE NEWSWIRE) -- There is an uptrend in the research of psychedelic substances for treating mental illnesses like addiction, depression, anxiety and posttraumatic stress disorder (PTSD). Researchers at Johns Hopkins Universityi and the Multidisciplinary Association for Psychedelic Studies (MAPS)ii are pioneering research on psychedelic medicine, while the Yale Psychedelic Science Groupiii is initially focused on contemporary clinical research and the mechanisms of action of psychedelic treatments. Both Forbesiv and CNNv noticed the trend and recently published articles on the resurgence of research into psychedelics. As these researchers open new doors for the treatment of mental health issues, there exists a world of opportunity for the commercialization of research into psychedelics. Many investors are looking towards leaders in the cannabis industry as potential players in this field. As investor interest in psychedelic agents as adjuncts to psychotherapy or counseling for mental illness increases, it is opening a range of opportunity for companies that have successfully launched cannabis products including Ehave, Inc. (OTC Pink: EHVVF), Aphria Inc. (NYSE: APHA) (TSX: APHA), Canopy Growth Corporation (TSX: WEED), (NYSE: CGC), and Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF).
Ehave, Inc. (OTC Pink: EHVVF) just announced plans to enter the $88 billion mental health market with a letter of intent to acquire 100% of PsychedeliTech, a division of Israel based Israel Cannabis Limited (“iCAN”). Ehave management believes PsychedeliTech could be a leader in the commercialization of research into psychedelics for the treatment of anxiety, depression, and other mental illnesses. Upon closing of the transaction, iCAN Founder, Saul Kaye, will be appointed as a Chairman of Ehave’s to be formed subsidiary PsychedeliTech. With a large number of contacts in the industry, both Ehave, Inc. and PsychedeliTech intend to create an ecosystem to nurture the development of therapies using psychedelics. The ecosystem includes clinical trials, biosynthesis of psychedelic compounds, E-commerce, CPG’S, supply, dosage, delivery, data, conferences and business intelligence.
Created by the team behind CannaTech, PsyTech is positioned to be an incubator and discovery platform to elevate psychedelic medicine, foster normalization, and accelerate innovation utilizing Ehave’s Telemetry Engine and Ehave Dash. Ehave’s Dash enables developers, clinicians, researchers, doctors, hospitals, universities and ultimately prescribers of Psychedelic therapy to monitor the effectiveness of treatment, track patient compliance and verify treatment outcomes in a reliable and objective manner through insightful data. PsyTech is also involved in the inaugural PsyTech Summit will take place March 29-30, 2020 at the Hilton Hotel, on the Mediterranean Sea in Tel Aviv, Israel. Rick Doblin, Ph.D., Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS) will be the gathering’s keynote speaker. The landmark event will bring together scientists, innovators, regulators, investors, and advocates from around the world to expand minds to the potential of psychedelic medicine.
Other cannabis-related developments from around the markets include:
Aphria Inc. (NYSE: APHA) (TSX: APHA) announced Monday announced that it has received its European Union Good Manufacturing Practices certification (GMP certification) in respect of medicinal products for human use and investigational medicinal products for human use, from the Malta Medicines Authority at the Company's subsidiary, ARA - Avanti Rx Analytics. This clears the path for Aphria to start selling medical cannabis to pharmacies in Germany and other countries.
The GMP certification is important for Aphria to penetrate EU markets. Aphria expects to start its first shipments in the fourth quarter of fiscal 2020. The company has a June-to-May fiscal calendar. Aphria also lowered its revenue guidance for fiscal 2020. Aphria Inc. and its subsidiaries produce and sell medical marijuana in the form of capsules, oral solutions, and vaporizers through retail sales and wholesale channels. The Company's operations are based in Leamington, Ontario.
Canopy Growth Corporation (TSX: WEED), (NYSE: CGC) announced recently the Company has submitted its final documentation for its beverage facility to Health Canada in late June 2019 and subsequently received the license in late November 2019. In the seven weeks since receiving the license, the Company has made meaningful progress towards scaling the production process for its cannabis beverages from lab scale to commercial scale. Canopy Growth stated management remains very confident in the underlying beverage science and in its ability to scale production and deliver high quality, differentiated cannabis beverages to the market. However, the scaling process is not complete, and the Company is extending its to-market date while the internal teams complete the final steps. The Company also said cannabis beverages have disruptive power and in time, may introduce new consumers to the cannabis category. Canopy said management does not believe this delay will have a material impact on its FY20 revenue and that they intend to provide an update with the release of its Q3 2020 financial results.
Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) announced the next phase of its Social Equity License Education Assistance Program (LEAP) which includes programming and one-on-one consultations for Illinois craft grower, infuser and transporter licenses. Applications are due to the state on March 16 and the Department of Agriculture is expected to issue up to 40 craft grower licenses, up to 40 infuser licenses, and an unlimited number of transporter licenses on or before July 1, 2020. Dispensary applications were due January 2 with up to 75 awardees expected to be announced by May 1. In separate news, Chicago TV station WGN reported Tuesday that less than a month into Illinois' rollout of recreational marijuana, some worry severe supply shortages will affect patients who use cannabis as a medical treatment. Experts say supply shortages could go on for months, a frustrating situation for medical marijuana patients who say they can’t find what they’re looking for.
DISCLAIMER: Atlanta Capital Partners, LLC (ATLCP), which owns and operates Otcstockreview.com, is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. ATLCP is NOT affiliated in any manner with any company mentioned herein. ATLCP and its affiliated companies are news dissemination solutions providers and are not a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. ATLCP's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is never to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. ATLCP is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed ATLCP was compensated five hundred dollars for news coverage of current press releases issued by Ehave, Inc. by a non-affiliated third party. ATLCP holds no shares of any company named in this release.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and ATLCP undertakes no obligation to update such statements.
Media Contact Information:
dk@otcstockreview.com
(404) 856-9157
i https://hopkinspsychedelic.org
ii https://maps.org
iii https://medicine.yale.edu/psychiatry/education/residency/interest/psychedelic_science_group/
iv https://www.forbes.com/sites/sarabrittanysomerset/2020/01/12/psychadelic-events-are-going-mainstream-where-the-much-maligned-mushroom-industry-focuses-on-mental-health/#644bb26b402d
v https://www.cnn.com/2019/12/13/health/psilocybin-magic-mushrooms-depression-intl-hnk-scli-scn/index.html